[Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations].
Since its emergence in 1997, the highly pathogenic avian influenza A(H5N1) virus has posed the threat of causing a human pandemic. The question is whether it is feasible and advisable to attempt to give the population a certain degree of basic immunity to this virus. The recent development of effective adjuvants, which culminated this year in the approval of such a vaccine for human use in the European Union, indicates that the approach is possible, although many logistical problems remain. Pre-pandemic vaccination could be considered for the total population or for the most vulnerable groups, i.e. individuals receiving annual influenza vaccination. Another option is stock-piling vaccine, preferably separately from the adjuvant.
de Jong
J C
JC
Nationaal Influenza Centrum, Erasmus MC, afd. Virologie, Postbus 2040, 3000 CA Rotterdam. jc.de.jong@planet.nl
Osterhaus
A D M E
AD
D000276:Adjuvants, Immunologic; D004196:Disease Outbreaks / Q000517:prevention & control; D006801:Humans; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000276:immunology; D007251:Influenza, Human / Q000517:prevention & control*
D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines
Het eerste in Europa geregistreerde humane vaccin tegen de hoogpathogene vorm van een vogelgriepvirus: overwegingen.